Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexpropranolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 9/20 | 0.95 |
| ▸ | ADRB1 known ✓ | P08588 | 8/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.95 |
| ▸ | ADRB3 | P13945 | 6/20 | 0.95 |
| ▸ | NR2E1 | Q9Y466 | 5/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.95 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.95 |
| ▸ | HTR2C | P28335 | 4/20 | 0.95 |
| ▸ | HTR1A | P08908 | 4/20 | 0.95 |
| ▸ | LMNA | P02545 | 4/20 | 0.95 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.95 |
| ▸ | HTR2B | P41595 | 3/20 | 0.95 |
| ▸ | HTR2A | P28223 | 3/20 | 0.95 |
| ▸ | HTR6 | P50406 | 3/20 | 0.95 |
| ▸ | TSHR | P16473 | 3/20 | 0.95 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.95 |
| ▸ | SCN1A | P35498 | 2/20 | 0.95 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 0.95 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levopropranolol SCHEMBL5487447 | 1.00 | ADRB2 (0.95) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL614322 | 1.00 | ADRB2 (0.95) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL6126128 | 0.99 | ADRB2 (0.97) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL6511347 | 0.97 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL3955 | 0.97 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL1561135 | 0.97 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Dexpropranolol SCHEMBL29577201 | 0.97 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Levopropranolol SCHEMBL3956 | 0.97 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Propranolol SCHEMBL10537386 | 0.97 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 | |
| Levopropranolol SCHEMBL29355940 | 0.97 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3NR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004138-B1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LTD (IE) | 2024-03-13 | — | — | EP | disclosed |
| EP-4309673-A2 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | Bausch Health Ireland Limited (IE) | 2024-01-24 | — | — | EP | disclosed |
| US-20240002440-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | JPMORGAN CHASE BANK, N.A. | 2024-01-04 | — | — | US | disclosed |
| WO-2023244200-A1 | A MICROBIAL STEREOINVERSION METHOD FOR ENANTIOMERIC PURITY PRODUCTION OF PROPRANOLOL HC1, A DRUG SUBSTANCE | ANKARA UNIVERSITESI (TR) | 2023-12-21 | — | — | WO | disclosed |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-20230340023-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2023-10-26 | — | — | US | disclosed |
| EP-3708179-B1 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | BAUSCH HEALTH IRELAND LTD (IE) | 2023-10-04 | — | — | EP | disclosed |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-05-03 | — | — | US | disclosed |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-04-21 | — | — | US | disclosed |
| US-20210403508-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2021-12-30 | — | — | US | disclosed |
| WO-2006102674-A2 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006102069-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006086653-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006086562-A2 | PHENYLAZETIDINONE DERIVATIVES | MICROBIA, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| EP-1541175-A2 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | Schering Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| CN-1582168-A | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORP (US) | 2005-02-16 | — | — | CN | disclosed |
| EP-1385548-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | Schering Corporation (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORPORATION | 2003-04-10 | — | — | US | disclosed |
| WO-2002058731-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-1995020568-A1 | PHARMACEUTICAL PRODUCT COMPRISING A SALICYLATE OF AN ESTERIFIABLE BETA-BLOCKER | CAL INTERNATIONAL LIMITED (IE) | 1995-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340023-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | ADRB2 338/4885ADRB1 142/4885CYP2D6 3754/4885 |
| US-20210403508-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | ADRB2 338/4885ADRB1 142/4885CYP2D6 3754/4885 |
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | CYP46A1, FABP2, SREBF1 | ADRB2 346/4885ADRB1 193/4885CYP2D6 1549/4885 |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | ADRB2 338/4885ADRB1 142/4885CYP2D6 3754/4885 |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | ADRB2 338/4885ADRB1 142/4885CYP2D6 3754/4885 |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | ADRB2 338/4885ADRB1 142/4885CYP2D6 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.